CCCC Historical PE Ratio Notes

— C4 Therapeutics (ticker: CCCC) is a clinical-stage biopharmaceutical company focused on developing novel small-molecule drugs that harness targeted protein degradation (TPD) to treat cancer and other diseases. Using its proprietary TORPEDO™ platform, C4 Therapeutics designs molecules that induce the body's natural protein disposal system to selectively eliminate disease-causing proteins. Like many emerging biotech companies, C4 Therapeutics is in the early stages of product development, with revenues primarily driven by research collaborations & milestone payments rather than approved commercial products. As you review historical PE ratio charts & tables, it's important to recognize that CCCC has often reported negative or minimal earnings due to substantial research & development investments and the lack of recurring product sales. Because a PE ratio is calculated as price per share divided by earnings per share, this frequently results in non-meaningful (N/M), extremely high, or even negative PE ratios for CCCC at various times. These fluctuations reflect both the speculative nature of early biotech investing and investor expectations for the eventual profitability if and when C4's therapies reach the market. Understanding these fundamentals is key to interpreting the historical valuation metrics for the company.

On this page we presented the CCCC Historical PE Ratio information for C4 Therapeutics' stock. The average CCCC historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CCCC historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CCCC historical PE result, against the recent PE: when this page was posted on 8/11/2026, the most recent closing price for CCCC had been 3.87, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CCCC or any other given stock, valuation analysis for CCCC can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate C4 Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CCCC. Thanks for visiting, and the next time you need to research CCCC Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.